

# Global Graves Diseases Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets

https://marketpublishers.com/r/GAAF1DB2829EN.html

Date: August 2019

Pages: 45

Price: US\$ 1,799.00 (Single User License)

ID: GAAF1DB2829EN

# **Abstracts**

High levels of pipeline activity are being observed in Graves Diseases treatment during 2019. Clinical development activities are being undertaken by more than 5 companies including Apitope International NV, AV7 Ltd, Immunovant Sciences Ltd, Novartis AG, Omeros Corp and others.

A Significant contribution to the Graves Diseases pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Graves Diseases pipeline included 6 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.

Increased understanding of underlying causes of Graves Diseases condition and increased access to investments is encouraging growth of Graves Diseases drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.

The research study is structured to provide clear and actionable insights into Graves Diseases drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.

The report addresses the discovery, research and pre-clinical stage active Graves Diseases therapeutic candidates. Further, drugs in clinical stage including phase 1,



phase 2, phase 3 and pre-registration phases are also analyzed.

The current report examines the current Graves Diseases pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.

In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Graves Diseases. Further, orphan drug status, fast track designation, grants awarded and other special status for Graves Diseases pipeline compounds are also included. This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Graves Diseases pipeline and formulate effective research and development strategies.

#### RESEARCH METHODOLOGY

Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.

Scope of the Research

Graves Diseases Pipeline candidates-

Pre-clinical Phase: Discovery, research, pre-clinical

Early Phase: Phase 1 and Phase 2 Graves Diseases drugs

Late phase: Phase 3 and in-approval Graves Diseases drugs

Companies involved in the Pipeline-

Company overview

Snapshot

Graves Diseases therapeutic treatment activities



Details for each Graves Diseases drug candidate-

	<b>C</b>	
Snapshot		
Drug	name Name	
Alter	native Names	
Com	pany	
Origi	inator	
Phas	Se Se	
Mole	ecule Type	
Orph	nan Drug Status	
Drug Overvi	Drug Overview	
Mechanism	Mechanism of Action	
Current Stat	Current Status	
Trial Details		
Other details		
Pre-clinical t	Pre-clinical trials for each drug candidate	
Clinical trials	Clinical trials for each drug candidate	

Recent Graves Diseases therapeutic candidates, clinical trials, investments, grants, partnerships, licenses, awards and other news



# **Contents**

#### 1 TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

#### **2 EXECUTIVE SUMMARY**

- 2.1 Graves Diseases Disease Overview
- 2.2 Graves Diseases- Pipeline Snapshot
- 2.3 Graves Diseases- Pipeline Drugs by Phase
- 2.4 Graves Diseases- Pipeline Drugs by Company
- 2.5 Graves Diseases- Pipeline Drugs by Mechanism of Action

## **3 COMPANY WISE PIPELINE ANALYSIS**

- 3.1 Apitope International NV Graves Diseases Drug Pipeline, H2- 2019
- 3.2 AV7 Ltd Graves Diseases Drug Pipeline, H2- 2019
- 3.3 Immunovant Sciences Ltd Graves Diseases Drug Pipeline, H2-2019
- 3.4 Novartis AG Graves Diseases Drug Pipeline, H2- 2019
- 3.5 Omeros Corp Graves Diseases Drug Pipeline, H2- 2019
- 3.6 Rodos BioTarget Graves Diseases Drug Pipeline, H2- 2019

#### **4 PHASE 1 PIPELINE DRUG DETAILS**

- 4.1 Graves Diseases- Phase 1 Drug Details
- 4.2 Graves Diseases- Phase 1 Drug Overview
- 4.3 Graves Diseases- Phase 1 Mechanism of Action
- 4.4 Current Status
- 4.5 Trial Details

# **5 PHASE 2 PIPELINE DRUG DETAILS**

- 5.1 Graves Diseases- Phase 2 Drug Details
- 5.2 Graves Diseases- Phase 2 Drug Overview
- 5.3 Graves Diseases- Phase 2 Mechanism of Action
- 5.4 Current Status
- 5.5 Trial Details



#### **6 PHASE 3 PIPELINE DRUG DETAILS**

- 6.1 Graves Diseases- Phase 3 Drug Details
- 6.2 Graves Diseases- Phase 3 Drug Overview
- 6.3 Graves Diseases- Phase 3 Drug Mechanism of Action
- 6.4 Current Status
- 6.5 Trial Details

## 7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS

- 7.1 Graves Diseases- Pre-clinical Phase Drug Details
- 7.2 Graves Diseases- Pre-clinical Phase Drug Overview
- 7.3 Graves Diseases- Pre-clinical Phase Drug Mechanism of Action
- 7.4 Current Status
- 7.5 Trial Details

## **8 RECENT NEWS AND DEVELOPMENTS**

## 9 APPENDIX

- 9.1 About VPAResearch
- 9.2 Sources and Research Methodology



# I would like to order

Product name: Global Graves Diseases Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In

Approval Therapeutics, Companies and Markets

Product link: https://marketpublishers.com/r/GAAF1DB2829EN.html

Price: US\$ 1,799.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

# **Payment**

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <a href="https://marketpublishers.com/r/GAAF1DB2829EN.html">https://marketpublishers.com/r/GAAF1DB2829EN.html</a>

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <a href="https://marketpublishers.com/docs/terms.html">https://marketpublishers.com/docs/terms.html</a>

To place an order via fax simply print this form, fill in the information below and fax the completed form to  $+44\ 20\ 7900\ 3970$ 



